falsefalse

Post-Conference Perspectives: Urothelial Carcinoma 2022 Year in Review - Episode 5

Treatment Options for Frontline Metastatic Urothelial Carcinoma

,

Drs Aragon-Ching and Sridhar review the available treatment options for patients with frontline metastatic urothelial carcinoma and explain the design of an exciting clinical trial.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Incidence and Risk Factors for Urothelial Carcinoma
    EP. 2: Neoadjuvant Chemotherapy as Standard-of-Care for Muscle-Invasive Urothelial Carcinoma
    EP. 3: Neoadjuvant Chemotherapy in Urothelial Carcinoma: The CHECKMATE-274 Trial
    EP. 4: Neoadjuvant Chemotherapy in Urothelial Carcinoma: The IMvigor010 Study
    Now Viewing
    EP. 5: Treatment Options for Frontline Metastatic Urothelial Carcinoma
    EP. 6: Outcomes of the JAVELIN Bladder 100 Trial
    EP. 7: Metastatic Urothelial Carcinoma Treatment after Disease Progression on Avelumab
    EP. 8: Key Trial Data in Urothelial Carcinoma Treatment from ESMO 2022

    Related Content:

    Post-Conference Perspectives: Urothelial Carcinoma 2022 Year in ReviewUrothelial CancerOncLive News Network®
    FDA Approval Insights: Perioperative Durvalumab Plus Chemo in MIBC: With Matthew Galsky, MD
    CHMP Recommends EU Approval of Perioperative Durvalumab for Muscle-Invasive Bladder Cancer
    The OncFive: Top Oncology Articles for the Week of 5/18
    x